Gary Peltz
Gary Peltz is a Stanford geneticist whose work connects computational mouse genetics and AI with biomedical research. He earned an M.D. and Ph.D. at Stanford, trained in internal medicine and rheumatology at UCSF, and spent 17 years as a pharmaceutical research executive before becoming a full professor in 2008. His lab developed humanized-liver mice and computational genetics methods, built an AI pipeline for disease-gene discovery, and contributed to Google’s AI co-scientist. In 2025, he coauthored research that used the system to test liver-fibrosis drug candidates; as of October 2026, he is a professor and principal investigator at Stanford Medicine.
Timeline
-
1983–1989
Medical training at Stanford and UCSF
He earns an M.D. in medicine and a Ph.D. in structural biology at Stanford in 1983. At UCSF, he completes an internal medicine residency in 1985 and a rheumatology fellowship in 1989, then earns board certification in both fields in 1989.
-
2006–2008
Pharma research executive and professor
For 17 years, he works as a research executive at a large pharmaceutical company. Nature Publications selects him as one of the top 10 pharmaceutical research executives in 2006, and he becomes a full professor at Stanford Medical School in 2008.
-
2010–2011
Computational mouse genetics
He receives an NIH/NIDDK Transformative R01 award in 2010. In 2011, his lab develops a next-generation computational method that analyzes whole-genome sequences from 20 inbred mouse strains. Researchers use it to study genetic causes across 16 biomedical traits.
-
2011–2012
Humanized livers for drug testing
In 2011, Peltz and collaborators at Japan’s Central Institute for Experimental Animals produce a mouse whose liver can be humanized without ongoing liver toxicity. In 2012, Stanford researchers use the model to characterize clemizole, a potential part of a hepatitis C drug combination.
-
2022
AI for disease-gene discovery
With postdoctoral fellow Zhuoqing Fang, he creates an automated program that analyzes more than 10,000 mouse-trait data sets and searches 29 million papers for gene-disease links. His team uses the pipeline to identify genes linked to diabetes, obesity and cataract formation in mice.
-
2025
Coauthoring Google’s AI co-scientist
He coauthors Google Research’s introduction of AI co-scientist, a multi-agent system built with Gemini 2.0 to help scientists generate research hypotheses and proposals.
-
2025
Testing AI-selected liver drugs
He coauthors the 2025 paper “AI-Assisted Drug Re-Purposing for Human Liver Fibrosis,” which uses a multi-agent AI co-scientist to suggest repurposed drugs and tests 25 drugs in human hepatic organoids. Two AI-selected candidates reduce fibrosis and promote liver regeneration.
-
As of October 2026
Professor and principal investigator
He is a Professor and Principal Investigator in Stanford’s Department of Anesthesiology, Perioperative & Pain Medicine, and teaches Graduate Research in 2026–27. His laboratory develops genomic methods to identify genetic factors affecting disease susceptibility and translate findings into treatments. In May 2026, he uses Co-Scientist to search for medicines that can slow, stop or reverse liver fibrosis. In his experiments, vorinostat blocks 91% of a damage response that can drive liver scarring.
Sources and credits
Photo: We have no published photo of Gary Peltz yet. Send us a free-licensed photo.
- Gary Peltz’s Profile | Stanford Profiles
- Gary Peltz, MD, Ph.D. – Peltz Lab
- Mice with 'humanized' livers improve early drug testing, scientist show
- Using AI to find disease-causing genes
- Accelerating scientific breakthroughs with an AI co-scientist
- Google’s AI Co-Scientist Scores Two Wins in Biology
- Uncovering repurposed medicines to fight liver fibrosis
- People – Peltz Lab